Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Thioproperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.92 |
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.92 |
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.92 |
| ▸ | ADRA2A known ✓ | P08913 | 7/20 | 0.92 |
| ▸ | DRD1 known ✓ | P21728 | 7/20 | 0.92 |
| ▸ | ADRA1A known ✓ | P35348 | 7/20 | 0.92 |
| ▸ | SLC6A3 known ✓ | Q01959 | 7/20 | 0.92 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.92 |
| ▸ | ADRA2C known ✓ | P18825 | 6/20 | 0.92 |
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.92 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.92 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.92 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.92 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.92 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.60 |
| ▸ | GHSR known ✓ | Q92847 | 3/20 | 0.60 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.60 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.60 |
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.60 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioproperazine SCHEMBL29888916 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| Thioproperazine SCHEMBL2386850 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| Thioproperazine SCHEMBL29394708 | 0.96 | DRD3 (1.00) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| Thioproperazine SCHEMBL49902 | 0.96 | DRD3 (1.00) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| Thioproperazine SCHEMBL29372322 | 0.96 | DRD3 (1.00) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| Thioproperazine SCHEMBL11047988 | 0.91 | DRD3 (0.86) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| Thioproperazine SCHEMBL11047989 | 0.91 | DRD3 (0.86) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| SCHEMBL6946497 | 0.90 | DRD3 (0.85) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| SCHEMBL10136877 | 0.88 | DRD3 (0.85) | CYP3A4LMNACYP2D6CYP1A2DRD3 | |
| SCHEMBL10136896 | 0.88 | DRD2 (0.85) | CYP3A4LMNACYP2D6CYP1A2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-1968552-A1 | PACK | Reckitt Benckiser Healthcare (UK) Limited (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20080023365-A1 | Pack | RECKITT BENCKISER HEALTHCARE (UK) (GB) | 2008-01-31 | — | — | US | disclosed |
| WO-2007077421-A1 | PACK | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | disclosed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | disclosed |
| US-4717723-A | PHENOTHIAZINE DERIVATIVE TO CONTROL NAUSEA, VOMITING, VERTIGO | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 1988-01-05 | — | — | US | disclosed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | DRD3 685/4885DRD2 400/4885HTR1A 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.